NCT03904693: A trial that was reported late by Actelion
This trial has reported, although it was 57 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03904693 |
|---|---|
| Title | Prospective, Multi-center, Double-blind, Randomized, Active-controlled, Triple-dummy, Parallel-group, Group-sequential, Adaptive Phase 3 Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed Dose Combination in Subjects With Pulmonary Arterial Hypertension (PAH), Followed by an Open-label Treatment Period With Macitentan and Tadalafil Fixed Dose Combination Therapy |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 29, 2019 |
| Completion date | Aug. 23, 2022 |
| Required reporting date | Aug. 23, 2023, midnight |
| Actual reporting date | Oct. 19, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 57 |